Does mavacamten improve tolerability and reduce biomarkers of myocardial wall stress in adults with symptomatic non-obstructive hypertrophic cardiomyopathy?
In a Phase 2 study, mavacamten was well tolerated and significantly reduced biomarkers of myocardial wall stress (NT-proBNP and cTnI) in patients with symptomatic non-obstructive HCM.
Mavacamten, a novel myosin inhibitor, was well tolerated in most subjects with symptomatic nHCM. Furthermore, treatment was associated with a significant reduction in NT-proBNP and cTnI, suggesting improvement in myocardial wall stress. These results set the stage for future studies of mavacamten in this patient population using clinical parameters, including LVEF, to guide dosing. (A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy MAVERICK-HCM; NCT03442764).
Ho et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: